Appearance
Competitive Landscape
What MAUDE Can and Can't Tell You
Before diving into the data, understand what this analysis can and cannot do.
MAUDE CAN tell you:
- Failure patterns -- are the same mechanical issues repeating?
- Injury rates per event -- what % of reports involve patient harm?
- Temporal trends -- are failures accelerating, stable, or spiking?
- Attribution patterns -- is the manufacturer blaming users for design issues?
- Failure mode distribution -- mechanical vs. sterility vs. material
MAUDE CANNOT tell you:
- Absolute safety -- more events often means more market share, not worse safety
- Real complication rates -- only 1-10% of actual events get reported
- Precise market share -- no public source gives exact manufacturer share
- Head-to-head comparison by volume -- without knowing devices in field, raw counts are misleading
The Midline Market: Five Players
Every major midline catheter on the US market uses a guidewire for insertion -- except Stiletto. This is the structural fact that defines the competitive landscape.
| Manufacturer | Product | Share (est.) | Insertion | Guidewire | Differentiator |
|---|---|---|---|---|---|
| BD | PowerGlide Pro | ~70% | 5-step modified Seldinger | Yes | Market leader, distribution scale |
| ICU Medical | PowerWand | ~15% | Accelerated Seldinger (AST) | Yes | BIOGUARD antimicrobial coating |
| Teleflex | Arrow Midline | ~5% | Modified Seldinger | Yes | Arrowg+ard Blue antimicrobial |
| AngioDynamics | BioFlo Midline | ~5% | Guidewire-assisted | Yes | Endexo anti-thrombotic technology |
| Avia Vascular | Stiletto | <5% | 2-step SlipStream | No | Only guidewire-free midline |
Note: "Mini-midline" (PowerGlide category, <10cm) is distinct from traditional "midline" (MST-placed PICC cut to 20cm). BD dominates both at ~70% US share.
Two innovation stories are playing out in this market:
- Coating chemistry (ICU Medical, Teleflex, AngioDynamics) -- reduce infection or thrombosis after insertion
- Engineering simplicity (Stiletto) -- eliminate the failure mechanism during insertion
Both are valid. But only one addresses the 34.1% mechanical failure pattern in PowerGlide MAUDE data (n=132). And neither addresses the 30.3% manufacturing defect root cause.
#1: BD PowerGlide Pro (~70% Mini-Midline Share)
The incumbent. The device Stiletto must displace.
MAUDE Profile (PowerGlide Only)
| Product | Events | Injuries | Injury Rate | Deaths |
|---|---|---|---|---|
| PowerGlide Pro, Reinforced Tip | 73 | 21 | 28.8% | 0 |
| PowerGlide Pro | 34 | 12 | 35.3% | 0 |
| PowerGlide Midline | 14 | 10 | 71.4% | 0 |
| PowerGlide (other variants) | 45 | 12 | 26.7% | 0 |
| All PowerGlide | 224 | ~75 | ~33.5% | 0 |
For context, BD's other Power-line products:
| Product Line | Events | Injuries | Injury Rate | Deaths |
|---|---|---|---|---|
| PowerPort (ports) | 2,510 | 1,844 | 73.5% | 62 |
| PowerPICC | 2,104 | 183 | 8.7% | 0 |
| PowerMidline | 53 | 7 | 13.2% | 0 |
| PowerLoc | 282 | 11 | 3.9% | 0 |
The pattern: PowerGlide's 33.7% injury rate is 4x higher than PowerPICC (8.7%) and 9x higher than PowerLoc (3.9%). Same manufacturer, same quality systems -- the difference is the insertion mechanism.
Failure Modes (n=132 extracted PowerGlide events)
34.1% generic mechanical + 20.5% specific insertion failures. The "specific" category includes catheter tip separation, needle tearing through cannula, guidewire breakage, catheter shearing -- all insertion-mechanism failures that would be prevented by guidewire-free design:
- Catheter fracture at needle bevel (chevron/V-shaped break pattern)
- Catheter tip separation during insertion
- Needle tearing through cannula during retraction
- Guidewire breakage during retraction
- Needle failed to retract
The long tail (41.2%) includes clinical study batch reports: catheter occlusion, dislocation, infection, accidental removal -- dwell-time issues rather than insertion failures.
Root Cause Attribution (n=132 extracted)
| Root Cause | Count | % |
|---|---|---|
| User error | 65 | 49.2% |
| Manufacturing defect | 40 | 30.3% |
| Unknown | 22 | 16.7% |
| Design flaw | 3 | 2.3% |
| Wear | 2 | 1.5% |
Two stories in this data:
Story 1 -- User error (49.2%). Clinicians pulling catheters against needle bevels, inserting against resistance. 65 events blamed on user error, 56 justified (42.4%). The unjustified gap is small (9 events, 6.8%) -- not a strong blame-shifting signal, but no longer zero.
Story 2 -- Manufacturing defect (30.3%). Nearly 1 in 3 extracted failures attributed to production quality issues. This is separate from insertion technique -- it's the catheter itself arriving defective. Needle retraction failures, cannula tears from manufacturing, component quality issues.
The Stiletto argument now has two prongs:
- Error-proofing -- guidewire-free design prevents the 49.2% user error failures
- Quality differentiation -- 30.3% manufacturing defects is a BD production quality issue that Stiletto can compete against on reliability
BD Recall History
Four enforcement actions found -- all packaging/kit issues, not the catheter itself:
| Date | Issue | Class |
|---|---|---|
| Aug 2014 | Saline flush syringe in kits with open seals | II |
| Mar 2020 | Kit missing lidocaine (655 units) | II |
| May 2023 | Medline probe cover kit -- seam barrier issue | II |
| May 2023 | Medline ultrasound gel sterility issue | II |
No safety recalls on the catheter itself despite 224 MAUDE events with consistent mechanical failure pattern. The dominant failure mode (catheter shearing during insertion) has never triggered FDA enforcement.
BD Strengths & Weaknesses
Why BD wins today: 70% mini-midline share, distribution scale, GPO contracts, training infrastructure, inertia ("we've always used BD").
Where BD is vulnerable: Two distinct failure streams. (1) 34.1% mechanical + insertion-related failures are design-inherent -- the catheter-against-needle-bevel mechanism. Training reduces frequency but can't eliminate risk. (2) 30.3% manufacturing defects are a production quality issue -- needle retraction failures, cannula tears from manufacturing. Stiletto eliminates the first and can compete on the second.
Honest Assessment
Most PowerGlide failures are genuine technique errors. BD's user error attribution is accurate. The competitive argument isn't "BD blames users unfairly" -- it's "good engineering should prevent predictable technique errors from harming patients." Device linkage at 99.3% overall.
#2: ICU Medical PowerWand (~15% Share)
Formerly Smiths Medical. The #2 competitor and the product most likely to be on the shelf next to PowerGlide.
Product Profile
| Spec | Value |
|---|---|
| Insertion | Accelerated Seldinger Technique (AST) -- still guidewire-based |
| Sizes | 4 Fr and 5 Fr; 6 cm and 8 cm lengths |
| Power injectable | 300 psi / 5 ml/sec |
| Flow rates | 130 ml/min (4 Fr), 160 ml/min (5 Fr) gravity |
| Max dwell | 29 days |
| Material | CHRONOFLEX C with BIOGUARD Technology |
The BIOGUARD Story
ICU Medical's pitch is infection prevention, not insertion simplicity. BIOGUARD is an antimicrobial material that:
- Inhibits bacterial attachment (in vitro studies)
- Reduces thrombus formation (in vivo studies)
- Multiple independent studies show BSI reduction when combined with clinical protocols
This is a real differentiator -- but it addresses a different problem than Stiletto solves. BIOGUARD prevents infection after insertion. Stiletto prevents mechanical failure during insertion.
MAUDE Profile
Zero device-linked events in our database. One narrative mention across 2.48M events. This tells us nothing about safety -- PowerWand has meaningful market share but our device linkage (18.9%) likely doesn't capture it.
Competitive Positioning
Against BD: PowerWand competes on infection prevention. "Same insertion technique, better material."
Against Stiletto: PowerWand still uses a guidewire. It inherits the same mechanical failure mode risk as PowerGlide, even if the coating reduces infection. These are different value propositions solving different problems.
In a sales conversation: If the prospect uses PowerWand, don't attack the antimicrobial story -- it's defensible. Focus on the insertion mechanism: "BIOGUARD reduces infection after placement. SlipStream eliminates the mechanical failure that happens during placement. Both matter."
#3: Teleflex Arrow Midline (~10% Share)
Teleflex is primarily a CVC and PICC company. Their midline is a line extension, not their flagship.
Product Profile
| Spec | Value |
|---|---|
| Insertion | Modified Seldinger -- guidewire-based |
| Sizes | 4.5 Fr and 5.5 Fr |
| Power injectable | 5 ml/sec through distal lumen |
| Antimicrobial | Arrowg+ard Blue Advance (99.99% colonization reduction, 29 days) |
MAUDE Profile
| Metric | Value |
|---|---|
| Arrow Midline events | 9 |
| Injuries | 7 |
| Injury rate | 78% (n=9, too small) |
| Failure modes (extracted) | n=2 only: 1 guidewire tip separation, 1 material |
Nine events is not enough to draw conclusions. The 78% injury rate echoes the PowerGlide pattern, but n=9 is anecdotal, not statistical.
Competitive Positioning
Against BD: Arrow competes on antimicrobial coating (Arrowg+ard Blue). Similar to PowerWand's pitch.
Against Stiletto: Same guidewire-based insertion. Same category of mechanical failure risk. Teleflex's midline is not a major competitive threat in head-to-head situations -- they're more likely to lose to BD on distribution than to Stiletto on design.
Key fact: Teleflex's real strength is CVCs and PICCs (Arrow CVC 3-Lumen: 19 events, Arrow Ultraflex IAB: 18 events). Their midline is a secondary product line.
#4: AngioDynamics BioFlo (~8% Share)
The most technically interesting competitor. AngioDynamics competes on material science, not insertion mechanism.
Product Profile
| Spec | Value |
|---|---|
| Insertion | Guidewire-assisted |
| Technology | Endexo -- anti-thrombotic catheter surface |
| Power injectable | 325 psi (varies by size: 2-6 ml/sec) |
The Endexo Story
Endexo is a surface modification technology that integrates into the catheter material (not a coating that degrades). AngioDynamics' clinical claim: 94% less thrombus accumulation vs BD PowerGlide (measured by platelet count).
This is a strong clinical argument. Thrombus formation is the leading cause of catheter failure during dwell time. If Endexo works as claimed, it extends catheter life and reduces occlusion-related complications.
MAUDE Profile
| Metric | Value |
|---|---|
| BioFlo events (non-port) | 23 |
| Injuries | 16 |
| Injury rate | 70% (n=23) |
| Failure modes (extracted) | n=6: 67% mechanical, 17% sterility, 17% material |
BioFlo also shows a mechanical failure majority, but n=6 is too small to compare patterns. The 70% injury rate is in the same range as BD's midline products -- suggesting the guidewire insertion mechanism (which BioFlo also uses) may be the common factor.
Competitive Positioning
Against BD: "Better material science. Less thrombus. Longer catheter life." -- a compelling clinical argument.
Against Stiletto: BioFlo solves the dwell-time problem (thrombosis). Stiletto solves the insertion-time problem (mechanical failure). In a head-to-head, the question is which failure mode the facility cares about more.
The opening: If a facility is evaluating BioFlo, they're already willing to switch from BD. That's the hardest part. Position Stiletto as "solves a different problem, and it's the problem that causes the most dramatic adverse events (retained fragments, surgical retrievals)."
#5: Other Players
Cook Medical -- ~10% Share (Vascular Access, Not Midline)
Stents and interventional accessories. Minimal midline presence. Not a direct competitor.
Vygon -- ~8% Share (Europe)
Lifecath PICC and Nutricath lines. Minimal US MAUDE presence (<10 events). European-focused. Not a near-term US competitive threat.
The Guidewire Problem: Structural Insight
This is the sharpest insight from the data and the one that frames every competitive conversation.
Every guidewire-based midline inherits the same mechanical failure risk:
- Catheter pulled against sharp needle bevel during repositioning
- Guidewire kinks under torque
- Catheter material shears at stress concentration point
ICU Medical and Teleflex mitigate post-insertion risk with antimicrobial coatings. AngioDynamics mitigates dwell-time risk with anti-thrombotic surfaces. None of them address the insertion-time mechanical failure that drives the 54.6% combined failure mode in PowerGlide's data (34.1% mechanical + 20.5% specific insertion failures, n=132).
49.2% of PowerGlide failures are attributed to user error, and 30.3% to manufacturing defects. The users making technique errors are a real factor -- but nearly a third of failures are production quality issues that have nothing to do with clinician technique. Stiletto eliminates the insertion mechanism failures AND competes on manufacturing reliability.
Head-to-Head Comparison
| Dimension | BD PowerGlide | ICU Medical PowerWand | Teleflex Arrow | AngioDynamics BioFlo | Stiletto |
|---|---|---|---|---|---|
| Guidewire | Yes | Yes | Yes | Yes | No |
| Insertion steps | 5 | 3-4 (AST) | 5 | 5 | 2 |
| Power injectable | Yes | Yes | Yes | Yes | Yes |
| Antimicrobial | No | BIOGUARD | Arrowg+ard | No | No |
| Anti-thrombotic | No | Partial | No | Endexo | No |
| MAUDE injury rate | ~33.5% (n=224) | No data | 78% (n=9) | 70% (n=23) | No data |
| Mechanical failure % | 34.1% (n=132) | No data | n=2 | 67% (n=6) | No data |
| Mfg defect root cause | 30.3% (n=132) | No data | No data | No data | No data |
| Market share | ~70% | ~15% | ~5% | ~5% | <5% |
| GPO penetration | Deep | Moderate | Moderate | Limited | Limited |
| Sales force | Large | Medium | Large (CVC focus) | Small | Small |
Why We Don't Compare Raw Event Counts
BD has ~70% mini-midline share with hundreds of thousands of devices deployed. Comparing raw MAUDE event totals across products with different installed bases is comparing market share, not safety. Rates and patterns are the meaningful metrics.
PowerGlide Timeline: 2025 Acceleration
With 4.8x more data than the original analysis (224 vs 46 events), the 2025 pattern is clear.
| Period | Events/Month | Injuries/Month | Pattern |
|---|---|---|---|
| H2 2024 | 1-5 | 0 | Low baseline |
| Jan-May 2025 | 20-26 | 3-7 | Sustained elevation |
| Jun-Sep 2025 | 9-17 | 2-3 | Moderate |
| Oct 2025 | 35 | 15 | Spike |
| Nov 2025 | 3 | 3 | Drop (possibly incomplete data) |
The Oct 2025 spike (35 events) includes clinical study batch reports, but Jan-May 2025 shows sustained 20-26 events/month -- a real increase from baseline. This could reflect growing PowerGlide adoption (more devices = more events) or a genuine signal. Without procedure volume denominators, we can't distinguish adoption growth from safety trend.
Updated Assessment
The 2025 acceleration is real but ambiguous. Do not characterize it as a quality crisis -- but do not dismiss it as purely clinical trial artifact either. The sustained Jan-May elevation suggests increased real-world reporting.
Signals to Watch
| Signal | What It Means | Current Status |
|---|---|---|
| BD recall on PowerGlide mechanism | Design flaw confirmed by FDA | No recall on catheter itself |
| ICU Medical PowerWand MAUDE events | First real safety signal for #2 player | Zero events linked |
| Hospital system switches from BD | Market movement | Isolated cases |
| AngioDynamics Endexo clinical data | Strengthens or weakens anti-thrombotic claim | Monitoring |
| New 510(k) entrants | Market fragmentation | Monitoring |
Strategic Takeaways
Every competitor uses a guidewire. Stiletto is the only midline that eliminates it. This is a structural differentiator, not a feature comparison.
Two innovation stories. Coating chemistry (ICU Medical, Teleflex, AngioDynamics) vs. engineering simplicity (Stiletto). The coatings address post-insertion complications. Stiletto addresses the insertion failure itself.
BD has two vulnerabilities. (1) Design-inherent insertion failures (34.1% mechanical) that training can reduce but not eliminate. (2) Manufacturing defects (30.3%) that are a BD production quality problem, not a clinician problem.
The error-proofing argument plus quality. 49.2% user error (mostly justified). "Your clinicians are making predictable errors with PowerGlide. Stiletto makes that error impossible." Plus: "30.3% of PowerGlide failures are manufacturing defects. That's BD's quality system, not your clinicians."
PowerWand is the most relevant #2 competitor. Same insertion technique as BD but with an antimicrobial story. If a facility switches from BD to PowerWand, they've solved infection risk but not mechanical failure risk.
BioFlo is the most scientifically interesting competitor. Endexo (94% less thrombus vs PowerGlide) is a real clinical claim. If a facility is evaluating BioFlo, they're already willing to switch -- that's the hard part.
No catheter-specific recalls on PowerGlide despite 224 events. All 4 enforcement actions are kit/packaging issues (flush syringes, lidocaine, probe covers). The dominant mechanical failure pattern has never triggered FDA action -- suggesting FDA considers it a use-technique issue, not a device defect.
Data: FDA MAUDE via ScanPath ClickHouse. PowerGlide: 224 device-linked events, 132 with LLM extraction. BD Power line total: ~5,100 events. Arrow Midline: 9 events. BioFlo: 23 non-port events. PowerWand: 0 linked events. Stiletto: 0 linked events. Device linkage at 99.3% overall. See Methodology for full data quality assessment.